Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

rtain

investments.

(6) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(7) To exclude the DoD Tricare program reversal as a result of the U.S.

Court of Appeals September 2006 ruling.

(8) To exclude charges associated with the settlement of the PROVIGIL

patent litigation ($6.0 million) and employee severance costs

associated with the European integration and restructuring ($4.0

million).

(9) To exclude charges related to the impairment of an intangible asset.

(10) To exclude the write-off of deferred debt issuance costs related to

the Zero Coupon convertible subordinated notes.

(11) Amounts shown no longer exclude the impact of SFAS 123(R). The

earnings press release issued on November 2, 2006 reflected

adjustments of $11.6 million in each of Research and development and

Selling, general and administrative expenses and $8.8 million in

Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

"ADJUSTED" CONSOLIDATED SALES DETAIL *

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $202,202 $14,904 $217,106

GABITRIL 12,952 881 13,833

CNS 215,154 15,785 230,939

ACTIQ
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Corporation adds advanced cholesterol testing capabilities, ... a,cardio-diagnostic company, today announced that its VAP(R) ... newly released health,assessment, BiophysicalCheck., The announcement ... unique ability to,identify far more areas of ...
... 31 InNexus,Biotechnology Inc., (TSX VENTURE: IXS; ... drug development company commercializing the,next generation of ... Linking,(DXL(TM)) technology, will present at IBC,s 13th ... Innovative Therapeutics (DDT) Conference being,held in Boston ...
... Alsius Corporation,(Nasdaq: ALUS ), the worldwide ... ill patients, today,announced that it will hold a ... and provide a corporate update. Bill Worthen,president and ... p.m. Pacific Time,(4:30 p.m. Eastern Time) on Thursday, ...
Cached Biology Technology:VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment 2VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment 3InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBC's Annual World Congress Conference in Boston on Aug 6th 2Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... A female moth sitting on a goal post could attract ... And even if she switched her scent over time, the male ... gene in his antenna. A team of researchers led by ... how it adapted to even the slightest change in the chemicals ...
... -- Tissue implants made of cells grown on a ... help heal arteries scarred by atherosclerosis and other vascular ... work better than others. MIT researchers led by ... Professor of Health Sciences and Technology, have now shown ...
... and his colleagues have received a National Institutes of Health ... most basic messaging system affect cellular processes. ... will receive more than a million dollars over five years ... cells. The goal is to create techniques to generate and ...
Cached Biology News:Team discovers reason that male moths can keep finding females 2Team discovers reason that male moths can keep finding females 3Success of engineered tissue depends on where it's grown 2Success of engineered tissue depends on where it's grown 3NIH backs Rice University study of delay in gene transcription networks 2
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Human Jagged 2 Biotinylated Affinity Purified PAb...
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)...
Biology Products: